Medindia

X

NOVARTIS SCHIZOPHRENIA TREATMENT FANAPT(TM) (ILOPERIDONE) TABLETS NOW AVAILABLE FOR USE IN THE US

Monday, January 11, 2010 General News J E 4
Advertisement
Schizophrenia is a Chronic, Severe and Disabling Mental DisorderAffecting 2.4 million Americans

Novartis announced that Fanapt(TM) (iloperidone), the company'sschizophrenia treatment, is now available for use across the US. Fanapt is atwice-daily, oral antipsychotic, approved by the US Food and DrugAdministration (FDA) in May 2009 for the acute treatment of schizophrenia inadults.

Schizophrenia is a chronic, severe and disabling mental disorder,affecting 2.4 million Americans. Despite the availability of several agentsfor treatment, as many as 74% of all patients discontinue their medicationbefore completing 18 months of treatment. People with schizophrenia havevarying levels of response and tolerance to available therapies. More than aquarter of patients change their medications within a year, with a mean timeto switching of 100 days.

Fanapt is indicated for the acute treatment of schizophrenia in adults.In clinical trials treatment with Fanapt resulted in significant improvementin symptoms of schizophrenia as demonstrated on two major scales formeasuring the positive and negative symptoms of the disorder.

NEWS: Fanapt Proven Effective for the Treatment of Schizophrenia inAdults - Despite Available Medications, There Remains a Need for AdditionalTreatment Options

FORMAT: B-roll and Soundbites

ADDITIONAL RESOURCES: Video, contact information and more available at:http://multivu.prnewswire.com/broadcast/41920/press.html

VIDEO PROVIDED BY: Novartis Pharmaceuticals Corporation

Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations,1-800-653-5313 EXT. 3SATELLITE FEEDS: Monday, January 11th, 2010 Monday, January 11th, 2010 3:30 AM - 3:45 AM ET 1:15 PM - 1:30 PM ET Galaxy 19 AMC 3 C-Band C-Band Transponder 20 Transponder 3 Downlink Freq. 4100 Horizontal Downlink Freq. 3760 Horizontal

SOURCE Novartis Pharmaceuticals Corporation
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Gerresheimer Sets up New Production Facility for I...
S
Sanofi-aventis Commences Tender Offer for All Outs...